Events | Financial News | News

Strategy update: IDL Diagnostics

Nov 28, 2025

A strategy update with IDL Diagnostics was held on November 27th at Redeye, where CEO Anders Hultman and the management team presented recent achievements, spotlighted key initiatives, and discussed future opportunities looking toward 2026 and beyond. After their presentation, Redeye analyst Oscar Bergman moderated a Q&A session.

See the presentation here

CACLP and meeting with new distributor

Mar 27, 2026 | ,

During CACLP in Xiamen, China’s largest IVD exhibition, IDL Diagnostics had the opportunity to meet a wide range of industry players, exchange valuable insights, and further explore the fast-evolving Chinese IVD market. The trip concluded in Tianjin with our first...

read more

Partnership Meetings and CLIA Focus in China

Mar 20, 2026 | ,

Anders Hultman, Gustav Sten, Xia Jiang and Marie Torstensson have been in Shanghai, China, to meet our partners within CLIA. Currently, we have one product on the market, TPS CLIA, as well as two products in development: TK1 CLIA and UBC CLIA. The purpose of the...

read more

IDL Diagnostics at EAU26

Mar 17, 2026 | ,

IDL Diagnostics attended the European Association of Urology (EAU) 2026 conference in London last week. We had valuable discussions with physicians who use our diagnostic biomarkers in clinical practice and research. A big thank you to everyone we met at EAU26! We...

read more